Primary liver cancer, one of the most common malignant tumors, leads to nearly 1 million deaths per year and remains a prominent target for therapy. 1−4 Surgical resection may be the mainstay of treatment for primary liver cancer and offers the chance of cure, but the 5-year survival rate from liver cancer has remained fairly static over the past decade, as chemotherapy is lacking in sensitivity and specificity. 5−7 Therefore, new measures are urgently needed for the treatment of this disease. Gene therapy represents a rational new approach to cancer therapy, which could provide an adjunct to conventional treatment and has recently become a new focus for researchers and clinicians within this field. 8−10 Tumor cells growing quickly in cancer stimulate the production of blood vessels, and these newly formed tumor vessels are usually abnormal in form and architecture. Furthermore, tumor tissue usually lacks effective lymphatic drainage. Nanovector, carrying encapsulated drugs, extravasate into the tumor interstitial space and passively target the tumor tissue. Once the drug is locally released the local concentration becomes many times larger than after conventional systemic intravenous administration. This type of passive targeting is known as "enhanced permeation and retention" (EPR) and the altered lymphatic drainage of the tumor contributes to this effect. Experiments suggest that extravasation into tumors can take place if their diameter is < 400 nm, and becomes more effective for sizes < 200 nm. 11 Gene therapy for liver cancer will allow the use of a target cell-specific expression system, enabling therapy selectively aimed at genes expressed in liver cancer cells, which will reduce damage to normal liver cells. 12−15 Gene therapy for liver cancer requires a vector that can safely and efficiently transfect target genes into the targeted organ. 14 Therefore, we constructed a recombinant plasmid, PEGFP-AFP-hTNFα, containing reporter gene green fluorescent protein and the hTNFα target gene under the control of an AFP enhancer. PEG-PEI/Fe 3 O 4 nanomagnetic fluid was used as a gene transfer vector, 16 recombinant plasmid PEGFP-AFP-hTNFα was electively transfected into AFP-positive hepatocellular carcinoma cells HepG2 in vitro.
PEG-PEI/Fe 3 O 4 nanomagnetic fluid, a gene transfer vector, is a fluid containing ultra-fine magnetic iron particles, which has both the magnetic characteristic of solid iron and the fluidity of a liquid. The fluidity of PEG-PEI/Fe 3 O 4 can be oriented and positioned by exposing it to magnetic fields, and has been applied in many areas, such as using target drug vectors, X-ray radiopaque contrast agents, and embolization agents. 17−20 By exposing tissue to alternative magnetic fields in vivo, nanomagnetic fluid can absorb electromagnetic energy and transform it into heat energy, which can increase the temperature of surrounding tissues, enabling its application as heat therapy in cancer treatment. Some studies have shown that PEG-PEI/Fe 3 O 4 nanomagnetic fluid, as a vector for chemotherapy, is phagocytized by cancer cells in vitro, and produces heat energy by absorbing electromagnetic wave energy in alternative magnetic fields in vivo. This characteristic was then used to kill cancer cells. 21, 22 Magnetic particles are evacuated from the body via the normal metabolic pathways involved in cancer cell apoptosis.
Materials and Methods

Materials
PEG-PEI/Fe 3 O 4 nanomagnetic fluid was prepared by our laboratory. DH5α coli were preserved by our center. pEGFP-N1 vector was purchased from Promega (Madison, WI, USA). Plasmid pMD18-T-hTNFα was a gift from the Cancer Research Institute of Central South University (Hunan, China). Restriction enzyme and ligase were purchased from Takara Biology Incorporation (Shiga, Japan). Lipofectamine™ 2000 was purchased from Qiagen Incorporated (Valencia, CA, USA). Hepatocellular carcinoma cells (HepG2) and cervical cancer cells (Hela) were provided by the China Center for Type Culture Collection of Wuhan University (Wuhan, China), and preserved by our center. The Methylthiazolyldiphenyl-tetrazolium bromide (MTT) Kit, fetal bovine serum (FBS), RPMI1640 medium, and TdT fluid were purchased from Sigma (St. Louis, MO, USA). The PCR and Trizol Kits were purchased from Gibco (Carlsbad, CA, USA). All other chemical reagents were obtained commercially as reagent-grade products.
Methods
Amplification and cloning of hTNFa and the AFP enhancer Primers were designed for polymerase chain reaction (PCR) amplification following the extraction of DNA from liver cancer tissues in patients with high expression of AFP, in accordance with locus of enhancer core sequences in AFP genes. 5 The length of amplified fragment was approximately 461 bp, and PCR products were separated and purified using gel electrophoresis and a 1.5% agarose gel. Following separation and purification, the PCR products were inserted into the PGEM-7Zf (+) vector to construct the plasmid pGEM-7Zf-AFP after sequencing. According to the gene sequence of hTNFα (NM: 000594) in GenBank, the pMD18-T-hTNFα plasmid was used as a template for PCR amplification. PCR amplification was performed and yielded products 702 bp in length. The PCR products were separated and purified on a 1.5% agarose gel (as above). Following separation and purification, PCR products were inserted into the PEGFP-N1 vector to construct the pEGFP-hTNFα plasmid.
Construction of recombinant plasmid PEGFP-AFP-hTNFa
pGEM-7Zf-AFP and pEGFP-hTNFα were digested with restriction enzyme HindIII and Xhol, and were then ligated using a ligation reaction system. The ligation reaction system was composed of T4 DNA ligase (1 μL), buffer (1 μL), double distilled water (4 μL), GEM-7Zf-AFP fragment (3 μL) and pEGFP-hTNFα fragment (1 μL), and was stored overnight at 16°C. The final recombinant plasmid PEGFP-AFP-hTNFα was constructed through ligation, transformation, amplification and identification.
Transfection of hTNFa in HepG2 and Hela cells mediated by PEG-PEI/Fe 3 O 4 nanomagnetic fluid
HepG2 cells and Hela cells, in the logarithmic phase, were seeded into 24-well plates until 70% confluence was reached. At this time cells were transfected with plasmid PEGFP-AFP-hTNFα/ nanomagnetic fluid complexes. The same transfection study was repeated at least three times. Fluorescence microscopy was used to evaluate the rate of gene transfection in HepG2 cells 12 hours after transfection.
Reverse transcription polymerase chain reaction (RT-PCR) for target gene, hTNFa, expression in the HepG2 cells
HepG2 cells were plated into 96-well tissue culture plates, which were divided into three experimental groups. The groups were the nanomagnetic fluid gene transfer group (ratio of plasmid DNA/nanomagnetic fluid complexes was 1:10), the liposome gene transfer group (ratio of plasmid DNA/liposome complexes was 1:10) and the plasmid control group (only plasmid pEGFP-AFP-hTNFα, without transfection vector). Total RNA extracted using a Trizol Kit was combined with hTNFα primers for PCR amplification 48 hours after transfection. The PCR products were separated and purified on the 1.5% agarose gel using electrophoresis.
Analysis of hTNFa gene expression in transfected HepG2 cells by western blot
As mentioned above, HepG2 cells were divided into three experimental groups. Medium was discarded 48 hours after transfection, and cells were rinsed three times with ice cold PBS buffer. Cells were then lysed in cell culture lysis buffer and total cell proteins were separated and purified via discontinuous SDS-PAGE gel electrophoresis. After electroblotting, the membrane was blocked, in blocking solution (5% non-fat milk), to prevent unspecific protein binding to antibodies. The membrane was incubated with primary antibody (goat anti-human TNFα polyclonal antibody, 1:100 dilution, Santa Cruz) in blocking solution at 4°C overnight with shaking. The antibody solution was then removed and the membrane washed three times. Finally, the membrane was incubated with an appropriate secondary antibody (horse anti-goat IgG/HRP, 1:400 dilution, Santa Cruz) for 2 hours at room temperature in 5% milk. Following this incubation period, antibody solution was removed and the membrane was washed three times. The membrane was soaked in HRPenzyme-linked antibody chromogenic solution, and was rinsed in distilled water after the target protein band on the gels were visible. Findings were compared with tubulin (loading control).
Gene transfection efficiency of the hTNFa gene mediated by different gene vectors
HepG2 cells were plated into 96-well culture plates, which were divided into two experimental groups: the nanomagnetic fluid gene transfer group and the liposome gene transfer group. Ratio of plasmid DNA/nanomagnetic fluid complexes was 1:5, 1:10 and 1:20 in the nanomagnetic fluid gene transfer group, 1:10, 1:20 and 1:40 in the liposome gene transfer group. Transfection efficiency of HepG2 cells was detected by fluorescence microscope 12 hours, 24 hours and 48 hours after transfection.
Detection of transfection efficiency using flow cytometry (FCM)
HepG2 cells were plated into 96-well tissue culture plates, which were divided into three experimental groups: the nanomagnetic fluid gene transfer group, the liposome gene transfer group and the plasmid control group (pEGFP-AFP-hTNFα, without transfection vector). HepG2 cells were transfected with plasmid DNA/gene vector complexes to determine the efficiency of each transfection method. HepG2 cells were transfected with only the pEGFP-AFP-hTNFα plasmid, without transfection vector in the plasmid control group. HepG2 cells were detected by flow cytometry after transfection. The same experiment was repeated five times.
Detection of the inhibitory effects of the recombinant plasmid PEGFP-AFP-hTNFa on HepG2 cells mediated by PEG-PEI/Fe 3 O 4 nanomagnetic fluid
HepG2 cells were plated into 96-well culture plates, which were divided into two experimental groups: the nanomagnetic fluid gene transfer group and nanomagnetic fluid control group (only PEG-PEI/Fe 3 O 4 nanomagnetic fluid, without recombinant plasmid PEGFP-AFP-hTNFα). HepG2 cells were transfected with plasmid DNA/gene vector complexes to determine transfection efficiency, but in the nanomagnetic fluid control group, HepG2 cells were transfected with only PEG-PEI/Fe 3 O 4 nanomagnetic fluid, without recombinant plasmid PEGFP-AFP-hTNFα. MTT solution (10 μL) was added into each well of both groups 24 hours, 48 hours, 72 hours and 96 hours after transfection. The medium was removed after cells were incubated at 37°C for 4 hours, whereupon 200 μL DMSO was added into each well to dissolve the formazan. Absorbance was measured on an ELISA plate reader with a test wavelength of 570 nm. Each group was designed to 4 Double-Pored, and data obtained was analyzed with statistical calculations to compare the survival rate of cells in each group at different periods. 
Detection of HepG2 cell apoptosis using FCM
Statistical analyses
Statistical calculations (Student t test) in each group were performed using SPSS software version 12.0. The statistical significance level was set at p < 0.05. Statistical calculations were performed with single faction variance analysis between groups.
Results
Amplification of AFP enhancer by PCR
The length of amplified fragment seen when PCR products were separated and purified on a 1.5% agarose gel was approximately 461bp ( Figure 1A) . This fragment size is consistent with that of the target fragment, and the length of the PCR amplified fragment was also consistent with that published on GenBank. 23 
Preparation and identification of PEGFP-AFP-hTNFa
The pGEM-7Zf-AFP plasmid was digested by Hind II and Xhol to obtain target fragments about 461 bp in length ( Figure 1B) . This finding suggested that AFP enhancer was successfully inserted into the pGEM-7Zf (+). The pEGFP-hTNFα plasmid was digested by EcoR I and Hind II . I to obtain a target fragment of 702 bp ( Figure 1C ), which indicated that the hTNFα gene was successfully inserted into the eukaryotic expression vector, PEGFP-N1.
PEGFP-AFP-hTNFα plasmids were digested by EcoR I and Hind III to obtain target fragments with a length of approximately 702 bp. Target fragments 461 bp long were also obtained when PEGFP-AFP-hTNFα was digested using Hind II and Xhol ( Figure 1D ). These findings indicated that AFP enhancer and the hTNFα gene were successfully inserted into the eukaryotic expression vector, PEGFP-N1.
Expression of PEGFP-AFP-hTNFa in HepG2 and Hela cells
HepG2 cells and Hela cells were observed by fluorescent microscopy (Figure 2A ). 24 hours after transfection, the total number of green fluorescent protein (GFP) positive of Hela cells were less than that of HepG2 cells. The total amount of GFP in HepG2 cells increased with hours, and reached a peak at 48 hours after transfection, which was then followed by a decrease in GFP signal. The total amount of GFP in Hela cells, however, did not markedly increase over time, which indicated that the AFP enhancer could potently increase high-level specific expression of an exogenous gene in AFP-positive cells.
Comparison of transfection efficiency between nanomagnetic fluid and liposomes
Transfection efficiency was the highest when the ratio of plasmid DNA/liposome was 1:40 and the ratio of plasmid DNA/nanomagnetic fluid was 1:10. HepG2 cells, in all groups, were transfected with plasmid DNA/gene vector complexes with the greatest transfection efficiency, as detected by FCM ( Figure 2B ).
Detection of the hTNFa gene in HepG2 cells using RT-PCR and western blot analysis
The products of the nanomagnetic fluid gene transfer group and liposome gene transfer group formed a RNA/cDNA band of 702 bp, which is consistent with the DL-2000 DNA Marker. However, the plasmid control group did not display the protein band at 702 bp ( Figure 3A) . Western blot analysis was performed to determine the molecular weight of the expression products. The products of the nanomagnetic fluid gene transfer group and liposome gene transfer group formed a specific protein band of 45 kDa, consistent with the molecular weight of tubulin. However, the plasmid control group did not display the protein band at 45 kDa ( Figure 3B) . The results suggested that PEG-PEI/Fe 3 O 4 nanomagnetic fluid had successfully transfected recombinant plasmid PEGFP-AFP-hTNFα into HepG2 cells as a gene vector in vitro, and the hTNFα gene had successfully integrated into the HepG2 cells.
The killing effect on HepG2 cells in vitro of the recombinant plasmid PEGFP-AFP-hTNFa mediated by PEG-PEI/Fe 3 O 4 nanomagnetic fluid
MTT assay was performed to determine the survival rate of the cells. The mean optical density of the nanomagnetic transfer group was lower than that of nanomagnetic control group in all periods following transfection. This difference was statistically significant, as determined by Student t test (p < 0.05). These results indicated that survival rate of transfected cells decreased, growth of transfected cells was inhibited, and survival rate of transfected cells was the lowest (70.9%) 48 hours after transfection (Figure 4 ).
Detection of apoptotic cells using FCM
The G1 phase peaks on the left side of recombinant gene transfer group are both peak types of hypodiploid cells, showing that the G1 phase of cell division had been blocked in this group ( Figure 5 ). The percentage of cells in the S/G2 phase decreased, suggesting that cells had undergone apoptosis. Apoptosis rate in the nanomagnetic fluid gene transfer group was the highest among all groups at 26.9%, but the lowest in the blank control group at 3.9%. Apoptosis rate in the nanomagnetic fluid gene group and nanomagnetic fluid transfer blank vector were close to that of the blank control group, indicating that apoptosis of cells was induced by the target hTNFα gene ( Figure 5 ).
Discussion
Human tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine, is synthesized and secreted by several types of cells, but especially by macrophages. It has been reported that TNFα has a strong anti-tumor effect, markedly inhibiting tumor growth by inducing tumor cell necrosis. 24 However, the clinical use of TNFα is severely limited by its high toxicity and unwanted side effects, such as severe hypotension, hyperpyrexia and organ failure. Higher doses of TNFα may not only exhibit higher cytotoxicity, but also lead to systemic toxicity, while the narrow therapeutic index of TNFα may limit its utility as an anticancer agent. 25, 26 A promising response to this problem is to transfect the TNFα gene into tumor cells in the hope of increasing its antitumor effects and decreasing unwanted side effects. 27, 28 In this study, we successfully constructed the recombinant plasmid PEGFP-AFP-hTNFα ( Figure  1C and Figure 2A) , and the use of PEG-PEI/Fe 3 O 4 nanomagnetic fluid specifically transfected the target hTNFα gene into AFP-positive HepG2 cells.
PEG-PEI/Fe 3 O 4 nanomagnetic fluid with a size range of 80-100 nm prepared by our group has many advantages, such as low toxicity, reducing damage to other organs, tissues and cells, ability to target orientation, and improving transfection efficiency. 16 Small size and magnetism of nanomagnetic carriers solves the problem of embolization failure and ectopic embolization in the period of cancer embolization therapy. PEG-modified nanomagnetic fluid prolonged the time of circulation in vivo, which avoided phagocytosis by phagocytic cells and enhanced biocompatibility. The fluid also has bystander effects and a killing effect on cancer cells. PEG-PEI/Fe 3 O 4 nanomagnetic fluid prepared by our group in our study, and a new gene transfer vector, have successfully transfected recombinant plasmid PEGFP-AFP-hTNFα into HepG2 cells in vitro. These findings suggest that the target gene mediated by PEG-PEI/Fe 3 O 4 nanomagnetic fluid was successfully transfected and expressed in the HepG2 cells. Furthermore, transfection efficiency was higher than that of liposome as a gene vector ( Figure  2A , Figure 2B ). Therefore, PEG-PEI/Fe 3 O 4 nanomagnetic fluid provided a perfect and new nonviral vector for gene therapy of liver cancer.
In the period of gene therapy for liver cancer, the use of target cell-specific expression systems will enable therapeutic gene selectively to liver cancer cells, which reduces damage to normal liver cells. 11−15 Previous studies show that the use of liver cancer-specific regulatory elements allow for therapeutic targeting of genes selectively expressed in liver cancer cells, such as the AFP promoter/ enhancer, the albumin promoter, and insulin-like growth factor II promoter. 29−31 The albumin promoter and insulin-like growth factor II promoter, however, are less used than the AFP promoter/ enhancer to make target gene selectively expressing liver cancer cells, because of non-specific expression of the albumin promoter and insulinlike growth factor II promoter in the liver cancer cells. AFP is expressed in high levels in the yolk sac and liver during embryonic development. 32, 33 In adults, levels of AFP are almost undetectable, except in patients who have liver cancer. We constructed a recombinant plasmid PEGFP-AFP-hTNFα containing reporter gene green fluorescent protein Fluorescence microscopy found PEGFP-AFP-hTNFα was highly expressed in the AFP-positive hepatocellular carcinoma cells HepG2 after transfection, but less expressed in the AFP-negative cervical cancer cells Hela (Figure 2A ). FCM suggested that PEGFP-AFP-hTNFα markedly inhibited AFPpositive HepG2 cell growth, but not AFP-negative cell growth (Figure 4 ). These results indicated that the AFP enhancer can specifically enhance the expression of target gene in cells positive for AFP. The hTNFα gene was therefore selectively expressed in liver cancer cells positive for AFP, and markedly inhibited AFP-positive HepG2 cell growth, but reduced damage to normal liver cells.
